[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Assembly Biosciences (ASMB)

Assembly Biosciences (ASMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 472,658
  • Shares Outstanding, K 15,893
  • Annual Sales, $ 72,300 K
  • Annual Income, $ -6,120 K
  • EBIT $ -12 M
  • EBITDA $ -14 M
  • 60-Month Beta 1.08
  • Price/Sales 6.80
  • Price/Cash Flow N/A
  • Price/Book 2.37

Options Overview Details

View History
  • Implied Volatility 86.61% (+7.26%)
  • Historical Volatility 49.89%
  • IV Percentile 19%
  • IV Rank 15.86%
  • IV High 165.07% on 09/17/25
  • IV Low 71.82% on 10/20/25
  • Expected Move (DTE 4) 1.53 (5.02%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 2
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 547
  • Open Int (30-Day) 426
  • Expected Range 28.95 to 32.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.71
  • Number of Estimates 1
  • High Estimate $-0.71
  • Low Estimate $-0.71
  • Prior Year $-1.33
  • Growth Rate Est. (year over year) +46.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.97 +17.35%
on 04/29/26
31.89 -4.44%
on 05/07/26
+2.06 (+7.23%)
since 04/10/26
3-Month
25.47 +19.63%
on 02/12/26
31.89 -4.44%
on 05/07/26
+3.11 (+11.39%)
since 02/11/26
52-Week
12.11 +151.65%
on 05/14/25
39.71 -23.25%
on 11/20/25
+18.24 (+148.98%)
since 05/09/25

Most Recent Stories

More News
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today...

ASMB : 30.26 (+1.75%)
Assembly Biosciences: Q1 Earnings Snapshot

Assembly Biosciences: Q1 Earnings Snapshot

ASMB : 30.26 (+1.75%)
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule...

ASMB : 30.26 (+1.75%)
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026

– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation...

ASMB : 30.26 (+1.75%)
Assembly Biosciences: Q4 Earnings Snapshot

Assembly Biosciences: Q4 Earnings Snapshot

ASMB : 30.26 (+1.75%)
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights

– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan...

ASMB : 30.26 (+1.75%)
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years –

ASMB : 30.26 (+1.75%)
GILD : 133.88 (+1.94%)
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion...

– 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179,...

ASMB : 30.26 (+1.75%)
Assembly Biosciences: Q3 Earnings Snapshot

Assembly Biosciences: Q3 Earnings Snapshot

ASMB : 30.26 (+1.75%)
Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

– Released positive Phase 1b interim results for long-acting helicase-primase inhibitor candidate ABI-5366 showing significant reductions in viral shedding rate and genital lesion rate in recurrent genital...

ASMB : 30.26 (+1.75%)

Business Summary

Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for...

See More

Key Turning Points

3rd Resistance Point 33.45
2nd Resistance Point 32.47
1st Resistance Point 31.11
Last Price 30.26
1st Support Level 28.77
2nd Support Level 27.79
3rd Support Level 26.43

See More

52-Week High 39.71
Last Price 30.26
Fibonacci 61.8% 29.16
Fibonacci 50% 25.91
Fibonacci 38.2% 22.65
52-Week Low 12.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.